In Silico Evaluation of the Binding Energies of Androgen Receptor Agonists in Wild-Type and Mutational Models
The Journal of Physical Chemistry B · 2023
DOI: 10.1021/acs.jpcb.3c01103 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, 2023. Verfasst von Ana Camila Campelo Albuquerque und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970 Natal-RN, Brazil. Hauptthemen laut MEDLINE: Androgens, Receptors, Androgen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior.
Abstract (Originalsprache)
Anabolic androgenic steroids (AAS) are substances with androgenic and anabolic characteristics. Among the many side effects of hormone therapy with AAS, the following stand out: heart problems, adrenal gland disorders, aggressive behavior, increased risk of prostate cancer, problems related to lack of libido and impotence. Such substances vary in the relationship between androgenic activity, and the activation of the androgen receptor (AR) is of fundamental importance for the singularity of the action of each AAS. In this sense, our study evaluates the aspects that comprise the interactions of testosterone agonists (TES), dihydrotestosterone (DHT) and tetrahydrogestrinone (THG) in complex with the AR. In addition, we also evaluated the impact of ligand-receptor affinity differences in a mutation model. We apply computational techniques based on density functional theory (DFT) and use, as methodology, Molecular Fractionation with Conjugate Caps (MFCC). The energetic specificities present in the interaction between the analyzed complexes attest that the highest affinity with the AR receptor is found for AR-THG, followed by AR-DHT, AR-TES and AR-T877A-DHT, respectively. Our results also show the differences and equivalences between the different agonists, in addition to evaluating the difference between the DHT ligand in complex with the wild-type and mutant receptor, presenting the main amino acid residues that involve the interaction with the ligands. The computational methodology used proves to be an operative and sophisticated choice to help in the search for pharmacological agents for various therapies that have androgen as a target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970 Natal-RN, Brazil.
- Applied Physics Department, University of Campinas, 13083-970 Campinas, São Paulo, Brazil.
Förderung
- Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
- Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior
Zitieren
APA
Albuquerque, A. C. C., Bezerra, K. S., de Fátima Vianna, J., Batista, S. O., de Lima Neto, J. X., de Oliveira Campos, D. M., Oliveira, J. I. N., Galvão, D. S., & Fulco, U. L. (2023). In Silico Evaluation of the Binding Energies of Androgen Receptor Agonists in Wild-Type and Mutational Models. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.3c01103
Vancouver
Albuquerque ACC, Bezerra KS, de Fátima Vianna J, Batista SO, de Lima Neto JX, de Oliveira Campos DM, et al. In Silico Evaluation of the Binding Energies of Androgen Receptor Agonists in Wild-Type and Mutational Models. The Journal of Physical Chemistry B. 2023. doi:10.1021/acs.jpcb.3c01103
BibTeX
@article{Albuquerque2023,
author = {Albuquerque, Ana Camila Campelo and Bezerra, Katyanna Sales and de Fátima Vianna, Jéssica and Batista, Sabrynna Oliveira and de Lima Neto, José Xavier and de Oliveira Campos, Daniel Melo and Oliveira, Jonas Ivan Nobre and Galvão, Douglas Soares and Fulco, Umberto Laino},
title = {In Silico Evaluation of the Binding Energies of Androgen Receptor Agonists in Wild-Type and Mutational Models},
journal = {The Journal of Physical Chemistry B},
year = {2023},
doi = {10.1021/acs.jpcb.3c01103}
}
EUVIMED